Kridis Wala Ben, Toumi Nabil, Chaari Hadil, Khanfir Afef, Ayadi Kamel, Keskes Hassib, Boudawara Tahia, Daoud Jamel, Frikha Mounir
Department of Oncology Habib Bourguiba Hospital, Sfax, Tunisia.
Rev Recent Clin Trials. 2017;12(1):19-23. doi: 10.2174/1574887112666170120100147.
The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40 to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and prognostic factors of this entity.
A systematic review of the literature was performed. Studies focused on the management of ES were considered for inclusion.
ES represents a model of multidisciplinary approach. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between the pediatric and medical oncologists. The overall 5- year survival of Ewing localized tumors was 70% versus 30% in metastatic ES.
The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose chemotherapy is still debated.
尤因肉瘤（ES）占恶性骨肿瘤的10%至15%，占儿童恶性骨肿瘤的40%至45%。本综述的目的是阐明该疾病的治疗结果和预后因素。
对文献进行系统综述。纳入聚焦于ES治疗的研究。
ES是多学科治疗方法的典范。欧洲和北美的多个国内和国际团队的努力以及儿科肿瘤学家和医学肿瘤学家之间的合作促成了ES多模式治疗策略的优化。尤因局限性肿瘤的总体5年生存率为70%，而转移性ES为30%。
ES的治疗包括新辅助化疗和辅助化疗，联合手术和/或放疗以控制原发部位及可能的转移性疾病。大剂量化疗的作用仍存在争议。
Zotero 插件